Our Press Releases | Association for Accessible Medicines

GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

May 12, 2019 | Rachel Schwartz

Response to 60 Minutes May 12, 2019: AAM Statement on the Importance of Competition to Promote Accessibility and Affordability of Medicines

May 8, 2019 | Rachel Schwartz

AAM Statement on Introduction of the Affordable Prescriptions for Patients Act

May 7, 2019 | Jeff Francer

AAM Statement: Senate Judiciary Committee Hearing on Patents and Drug Prices

Apr 24, 2019 | Jewel Smith

AAM Announces 2019 Associate Members

AAM Statement on House Energy & Commerce Passage of the CREATES Act

Apr 3, 2019 | Rachel Schwartz

AAM Statement on House Energy & Commerce Passage of the CREATES Act

Responding to the CY 2020 MA Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter

Apr 1, 2019 | Rachel Schwartz

AAM Response to CMS Final 2020 Call Letter

2019 Energy and Commerce Health Subcommittee Markup

Mar 27, 2019 | Rachel Schwartz

AAM Statement: 2019 Energy and Commerce Health Subcommittee Markup

Karin Hessler Joins AAM as Assistant General Counsel

Mar 18, 2019 | Rachel Schwartz

Karin Hessler Joins AAM as Assistant General Counsel

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Mar 11, 2019 | Rachel Schwartz

AAM Statement in Response to Administration's FY 2020 Budget Proposal

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 7, 2019 | Rachel Schwartz

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 5, 2019 | Rachel Schwartz

AAM Statement on Dr. Scott Gottlieb's Departure

AAM Statement on Avalere Report

Feb 28, 2019 | Rachel Schwartz

New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines